Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 8/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851592 | 0.86 | TP53 (0.50) | TP53CASRPOLB | |
| SCHEMBL4143434 | 0.84 | TP53 (0.44) | TP53CASRPOLB | |
| SCHEMBL4135896 | 0.82 | TP53 (0.43) | P2RX3TP53CASRPOLBTLR9 | |
| SCHEMBL4142349 | 0.81 | TP53 (0.51) | TP53CASRPOLBTNKS2 | |
| SCHEMBL4140446 | 0.81 | PDE10A (0.44) | P2RX3TP53CASRPOLB | |
| SCHEMBL4143059 | 0.79 | TP53 (0.49) | TP53CASR | |
| SCHEMBL4143019 | 0.79 | TP53 (0.49) | TP53CASRPOLB | |
| SCHEMBL4135630 | 0.79 | C5AR1 (0.50) | TP53POLB | |
| SCHEMBL4142867 | 0.77 | CASR (0.54) | P2RX3CASR | |
| SCHEMBL4143333 | 0.77 | P2RX3 (0.41) | P2RX3TP53CASRPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | P2RX3 1604/4885TP53 3696/4885CASR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.